Skip to main content

ResMed| company profile

  • RMD · NYSE
  • Medical devices
  • Health Care Equipment
  • S&P 500
$240.13+0.81%Close 17 Nov 2026 · Market value $33.61B

About ResMed|

ResMed is a digital health and cloud-connected medical device company that designs CPAP, bilevel, ventilation and high flow therapy devices, masks and accessories, diagnostic products, and cloud-based software for the treatment of sleep and breathing disorders. Its products are used predominantly in the home and to a lesser extent in hospitals, and it sells them through wholly owned subsidiaries and independent distributors in more than 140 countries. ResMed operates two segments: Sleep and Breathing Health and Residential Care Software. The Residential Care Software business provides cloud-based solutions to home medical equipment providers, home health and hospice providers, skilled nursing facilities, senior living communities and related residential care providers in the U.S. and Germany, among others. The company employs approximately 11,370 people.

A summary of the business section of the company's latest annual report, filed 13 Aug 2026.

Company facts

TickerRMD · NYSE
SectorMedical devices
IndustryHealth Care Equipment
IndexS&P 500
Fiscal year ends30 June
Reporting currencyUSD
CIK943819
Latest annual report10-K, filed 13 Aug 2026

Officers and directors

NameRoleShares ownedLatest Form 4
Michael FarrellChairman and CEO · Director604K · < 1%Shares withheld for tax, 11 Nov 2026
Brett SandercockChief Financial Officer57.0K · < 1%Sale under a 10b5-1 plan, 1 Apr 2026
Peter FarrellDirector56.3K · < 1%Shares withheld for tax, 11 Nov 2026
Justin LeongChief Product Officer51.7K · < 1%Grant or award, 14 Aug 2026
Ronald TaylorDirector24.8K · < 1%Grant or award, 20 Nov 2025
Karen DrexlerDirector21.1K · < 1%Grant or award, 20 Nov 2025
Carol BurtDirector18.8K · < 1%Grant or award, 20 Nov 2025
Harjit GillDirector10.9K · < 1%Shares withheld for tax, 11 Nov 2026
Michael RiderGlobal General Counsel9.6K · < 1%Shares withheld for tax, 11 Nov 2026
Desney TanDirector6.0K · < 1%Grant or award, 20 Nov 2025
John HernandezDirector5.1K · < 1%Grant or award, 20 Nov 2025
Jan De WitteDirector4.3K · < 1%Shares withheld for tax, 11 Nov 2026
Christopher DelOreficeDirector2.4K · < 1%Grant or award, 20 Nov 2025
Nicole Mowad-NassarDirector2.1K · < 1%Grant or award, 20 Nov 2025
Aaron BloomerChief Financial Officer—Shares withheld for tax, 11 Nov 2026
Ghoshal KaushikChief Commercial Officer, SaaS—Option exercise, 10 Mar 2025
SULPIZIO RICHARDDirector—Grant or award, 20 Nov 2024

Holdings as the latest proxy statement states them, all forms counted; the latest Form 4 line each filed. People appointed since the proxy are listed from their Form 4 filings.

RMD in the terminal

The business section of every annual report, officers' holdings and trades, and the company's filings as they arrive.